Company intelligence / Profile preview
Guangdong Zhaotai Cell Biotechnology
Foshan, Guangdong, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Guangdong Zhaotai Cell Biotechnology is actively developing CAR-T cell therapies for hematological tumors, with a focus on CD19 and CD22 targets. Their novel tandem CAR-T product, 192228zT2, is being manufactured at their GMP facility and is currently in Phase 1 clinical trials.
- Therapeutic areas
- HematologyOncology
- Modalities
- CAR-T cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Sino-American Shanghai Squibb
Beyond the preview
Go deeper on Guangdong Zhaotai Cell Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangdong Zhaotai Cell Biotechnology.